MX2017013028A - Mutantes de region constante (fc) con actividad funcional modificada. - Google Patents
Mutantes de region constante (fc) con actividad funcional modificada.Info
- Publication number
- MX2017013028A MX2017013028A MX2017013028A MX2017013028A MX2017013028A MX 2017013028 A MX2017013028 A MX 2017013028A MX 2017013028 A MX2017013028 A MX 2017013028A MX 2017013028 A MX2017013028 A MX 2017013028A MX 2017013028 A MX2017013028 A MX 2017013028A
- Authority
- MX
- Mexico
- Prior art keywords
- polypeptide
- mutation
- functional activity
- mutants
- chosen
- Prior art date
Links
- 230000005714 functional activity Effects 0.000 title abstract 2
- 230000035772 mutation Effects 0.000 abstract 5
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
Abstract
La presente invención se relaciona con un polipéptido que comprende una región Fc mutada y que tiene actividad funcional, mediada por la región Fc, que se modifica en comparación con la de un polipéptido parental, caracterizado porque la región Fc comprende por lo menos una combinación de 2 mutaciones, siendo la combinación seleccionada de entre: (i) una mutación seleccionada entre 326E, 326T, 352L, 378V, 378T, 396L, 397M, 421T, 334N, 334R, 307N y 394P; y (ii) por lo menos una mutación seleccionada de 226Y, 227S, 230S, 231V, 234P, 243I, 243L, 246R, 246E, 247T, 248E, 253F, 254F, 255W, 259A, 261R, 262A, 263A, 266M, 267N, 267G, 274E, 274R, 276S, 278H, 379A, 282A, 283G, 284L, 286I, 286Y, 287T, 288E, 288R, 290E, 298N, 302A, 305A, 307P, 308A, 308I, 308G, 309P, 312G, 315D, 316D, 319H, 320T, 320R, 320M, 322E, 323I, 333G, 339T, 349S, 325S, 334N, 334R, 336T, 340E, 343S, 345G, 349H, 350A, 352S, 359A, 361H, 362R, 363I, 366A, 373D, 375R, 377T, 378V, 378T, 380G, 383R, 385R, 389S, 389T, 392R, 393A, 393I, 394P, 396L, 397I, 397M, 398P, 405V, 405L, 410R, 412M, 414R, 421T, 423L, 423Y, 423S, 423P, 428T, 431V, 431T, 434K, 434S, 435R, 436H, 439R, 440G, 440N, 442F, 442P y 447N, siendo la numeración el índice de la EU o el equivalente de Kabat, y siempre que la mutación (i) no se lleve a cabo sobre el mismo aminoácido que la mutación (ii). La presente invención también se relaciona con el uso de tal polipéptido, con composiciones que lo comprenden y con métodos para preparar tal polipéptido.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1554101A FR3035879B1 (fr) | 2015-05-07 | 2015-05-07 | Mutants fc a activite fonctionnelle modifiee |
| PCT/FR2016/051068 WO2016177984A1 (fr) | 2015-05-07 | 2016-05-06 | MUTANTS Fc A ACTIVITÉ FONCTIONNELLE MODIFIÉE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017013028A true MX2017013028A (es) | 2017-12-08 |
Family
ID=54151308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017013028A MX2017013028A (es) | 2015-05-07 | 2016-05-06 | Mutantes de region constante (fc) con actividad funcional modificada. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11649271B2 (es) |
| EP (1) | EP3292145B1 (es) |
| JP (1) | JP6830903B2 (es) |
| KR (2) | KR20240116586A (es) |
| CN (2) | CN115073604A (es) |
| AU (2) | AU2016259124B2 (es) |
| CA (1) | CA2977010A1 (es) |
| DK (1) | DK3292145T3 (es) |
| ES (1) | ES3014454T3 (es) |
| FR (1) | FR3035879B1 (es) |
| MX (1) | MX2017013028A (es) |
| PL (1) | PL3292145T3 (es) |
| WO (1) | WO2016177984A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3035879B1 (fr) | 2015-05-07 | 2025-02-28 | Lab Francais Du Fractionnement | Mutants fc a activite fonctionnelle modifiee |
| FR3038517B1 (fr) * | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| EP3494134B1 (en) | 2016-08-02 | 2025-12-10 | Visterra, Inc. | Engineered polypeptides and uses thereof |
| CA3033661A1 (en) | 2016-08-12 | 2018-02-15 | Janssen Biotech, Inc. | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions |
| FR3064007A1 (fr) | 2017-03-20 | 2018-09-21 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Anticorps pour le traitement de cancers |
| FR3075200B1 (fr) * | 2017-12-15 | 2022-12-23 | Lab Francais Du Fractionnement | Variants avec fragment fc ayant une affinite augmentee pour fcrn et une affinite augmentee pour au moins un recepteur du fragment fc |
| CN111655718B (zh) * | 2017-12-19 | 2025-07-22 | Xencor股份有限公司 | 经过工程化的il-2 fc融合蛋白 |
| EP3805400A4 (en) * | 2018-06-04 | 2022-06-29 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule showing changed half-life in cytoplasm |
| MX2021002057A (es) * | 2018-08-21 | 2021-07-21 | Bioatla Inc | Proteinas condicionalmente activas con selectividad de ph. |
| CA3130582A1 (en) * | 2019-02-18 | 2020-08-27 | Courier Therapeutics, Inc. | Bispecific fusion protein using orthopoxvirus major histocompatibility complex (mhc) class i-like protein (omcp) and tumor-specific binding partner |
| KR20230005234A (ko) * | 2020-04-17 | 2023-01-09 | 얀센 바이오테크 인코포레이티드 | 생합성 당단백질 집단 |
| JP2023531141A (ja) * | 2020-05-21 | 2023-07-21 | ザイダス・ライフサイエンシーズ・リミテッド | Ｆｃバリアント及びその調製 |
| CN113186167B (zh) * | 2021-04-28 | 2021-11-30 | 中国食品药品检定研究院 | 用于测定抗cd20单克隆抗体药物adcp生物学活性的方法 |
| US20250297031A1 (en) * | 2022-06-29 | 2025-09-25 | Korea University Research And Business Foundation | Human fc variants having improved fcgriia binding selectivity |
| CN120769862A (zh) | 2022-10-25 | 2025-10-10 | 赛斯米克治疗公司 | 变体IgG FC多肽及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| FR2816319B1 (fr) | 2000-11-08 | 2004-09-03 | Millegen | Utilisation d'adn polymerase mutagene pour la creation de mutations aleatoires |
| US7355008B2 (en) * | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| FR2861080B1 (fr) * | 2003-10-20 | 2006-02-17 | Lab Francais Du Fractionnement | Anticorps presentant un taux de fucose et de galactose optimise |
| AU2005304624B2 (en) * | 2004-11-12 | 2010-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP2233500A1 (en) | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
| PL2486141T3 (pl) | 2009-10-07 | 2018-07-31 | Macrogenics, Inc. | Polipeptydy zawierające regiony fc i mające w wyniku zmian w zakresie fukozylacji ulepszoną funkcję efektorową, i sposoby zastosowania tych polipeptydów |
| SI3053932T1 (sl) * | 2010-02-19 | 2021-01-29 | Xencor, Inc. | Novi CTLA4-IG imunoadhezini |
| EP2537864B1 (en) * | 2011-06-24 | 2019-08-07 | Laboratoire Français du Fractionnement et des Biotechnologies | Fc variants with reduced effector functions |
| FR3012453B1 (fr) * | 2013-10-31 | 2015-11-13 | Lab Francais Du Fractionnement | Proteine chimerique dans le traitement de l’amylose |
| FR3035879B1 (fr) | 2015-05-07 | 2025-02-28 | Lab Francais Du Fractionnement | Mutants fc a activite fonctionnelle modifiee |
-
2015
- 2015-05-07 FR FR1554101A patent/FR3035879B1/fr active Active
-
2016
- 2016-05-06 MX MX2017013028A patent/MX2017013028A/es unknown
- 2016-05-06 WO PCT/FR2016/051068 patent/WO2016177984A1/fr not_active Ceased
- 2016-05-06 JP JP2017554315A patent/JP6830903B2/ja active Active
- 2016-05-06 DK DK16726133.8T patent/DK3292145T3/da active
- 2016-05-06 KR KR1020247024678A patent/KR20240116586A/ko not_active Ceased
- 2016-05-06 KR KR1020177031051A patent/KR102689154B1/ko active Active
- 2016-05-06 AU AU2016259124A patent/AU2016259124B2/en active Active
- 2016-05-06 CN CN202210707722.5A patent/CN115073604A/zh active Pending
- 2016-05-06 PL PL16726133.8T patent/PL3292145T3/pl unknown
- 2016-05-06 CA CA2977010A patent/CA2977010A1/en active Pending
- 2016-05-06 ES ES16726133T patent/ES3014454T3/es active Active
- 2016-05-06 US US15/554,022 patent/US11649271B2/en active Active
- 2016-05-06 CN CN201680025478.7A patent/CN107531794B/zh active Active
- 2016-05-06 EP EP16726133.8A patent/EP3292145B1/fr active Active
-
2022
- 2022-09-08 AU AU2022228151A patent/AU2022228151B2/en active Active
-
2023
- 2023-03-31 US US18/193,830 patent/US20230265155A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2977010A1 (en) | 2016-11-10 |
| CN115073604A (zh) | 2022-09-20 |
| AU2016259124A1 (en) | 2017-08-31 |
| KR20180004125A (ko) | 2018-01-10 |
| US20230265155A1 (en) | 2023-08-24 |
| JP2018515446A (ja) | 2018-06-14 |
| KR20240116586A (ko) | 2024-07-29 |
| AU2016259124B2 (en) | 2022-06-16 |
| CN107531794B (zh) | 2022-07-12 |
| ES3014454T3 (en) | 2025-04-22 |
| KR102689154B1 (ko) | 2024-07-29 |
| WO2016177984A1 (fr) | 2016-11-10 |
| US20180030111A1 (en) | 2018-02-01 |
| DK3292145T3 (da) | 2025-03-31 |
| CN107531794A (zh) | 2018-01-02 |
| PL3292145T3 (pl) | 2025-06-09 |
| JP6830903B2 (ja) | 2021-02-17 |
| EP3292145B1 (fr) | 2025-01-08 |
| AU2022228151B2 (en) | 2025-06-26 |
| FR3035879B1 (fr) | 2025-02-28 |
| BR112017023453A2 (pt) | 2018-07-31 |
| AU2022228151A1 (en) | 2022-09-29 |
| US11649271B2 (en) | 2023-05-16 |
| FR3035879A1 (fr) | 2016-11-11 |
| EP3292145A1 (fr) | 2018-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017013028A (es) | Mutantes de region constante (fc) con actividad funcional modificada. | |
| IL254919B (en) | Polypeptide-based shuttle agents for improving the transduction efficiency of polypeptide cargos to the cytosol of target eukaryotic cells, uses thereof, methods and kits relating to same | |
| PH12016501623A1 (en) | Compositions for the inactivation of virus replication and methods of making and using the same | |
| EA201890756A1 (ru) | Антитела, которые специфически связываются с tl1a | |
| NZ701324A (en) | Prostate-associated antigens and vaccine-based immunotherapy regimens | |
| MX354049B (es) | Método rápido para la clonación y expresión de segmentos génicos de regiones variables de anticuerpos cognados. | |
| PH12018500155A1 (en) | Recombinant orf virus vector | |
| PH12019502616A1 (en) | Approval workflow entrusting and re-entrusting methods | |
| UA113909C2 (xx) | Заповнювач, що містить титан, спосіб його виготовлення та його застосування | |
| Zhao et al. | Correction to “nonionic triblock and star diblock copolymer and oligomeric surfactant syntheses of highly ordered, hydrothermally stable, mesoporous silica structures” | |
| MX381723B (es) | Metodos novedosos para conjugacion de polipeptido mediada por enzimas usando sortasa. | |
| MX2023008256A (es) | Modificacion de polipeptidos de hemaglutinina de influenza transformados por ingenieria genetica. | |
| MX2018013556A (es) | Polipeptidos variantes con rendimiento mejorado y uso de los mismos. | |
| Fedorova et al. | Dependence of the combustion heat of coal on its chemical composition | |
| LI et al. | The clone, expression and site-directed mutagenesis of 3-ketosteroid-delta (1)-dehydrogenase from Arthrobacter simplex | |
| WO2015165472A3 (en) | Cold-active alpha-amylase | |
| Goltsova | World hydrogen movement: scientific communities of hydrogen energy and hydrogen material science-historical and modern aspects | |
| Capron et al. | Going abroad in search of higher productivity at home | |
| Mar et al. | Author Correction: Mammal diversity influences the carbon cycle through trophic interactions in the Amazon | |
| Shi et al. | Optimizing prokaryotic expression of a xylanase gene from the apple pathogen Valsa mali var. mali | |
| Kim | Field application case of environment-friendly concrete | |
| RU2015126450A (ru) | Мутантная рекомбинантная гепариназа I с повышенной удельной активностью из Pedobacter heparinus, фрагмент ДНК, кодирующий указанную гепариназу | |
| Li et al. | Cloning and expression of glutaminase new gene in the sauce billet metagenomic | |
| Yam | A visit by Prof. Sritawat Kitipornchai, Advisor of CNERC | |
| Cimarusti | What's the right way to ask whether someone is gay? |